GastroenterologyNews.net

Gastroenterology Xagena

Xagena Mappa
Medical Meeting
Cardiobase
Farmaexplorer.it

Search results for "Ulcerative colitis"

IBD ( inflammatory bowel diseases ) is a term referring to several chronic diseases that cause inflammation of the intestines, including ulcerative colitis and Crohn's disease. Symptoms for both con ...


Infliximab is the first biologic to show efficacy in two inflammatory bowel diseases ( IBD ), Crohn's Disease and ulcerative colitis. Results from two Phase III trials presented at Digestive Diseas ...


The results from a double-blind, multicenter phase II trial of the investigational drug MLN02 in patients with ulcerative colitis showed that MLN02 was more effective than placebo for the induction of ...


Patients with moderate-to-severe active ulcerative colitis treated with Infliximab ( Remicade ) at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at we ...


Two studies, published in the Clinical Gastroenterology and Hepatology, have showen that prescription painkillers are effective in easing the pain of patients with dormant inflammatory bowel disease ( ...


A study found that the risk of infertility in women triples after the most major surgery for the inflammatory bowel disease ulcerative colitis. The authors base their finding on a detailed analysi ...


In the past decades, prophylactic colectomy to prevent development of colorectal cancer substantially has improved prognosis in patients with familial adenomatous polyposis ( FAP ). The mortality patt ...


Takeda Pharmaceutical has announced top-line results from the international, randomized, placebo-controlled, double-blind GEMINI II pivotal phase 3 trial. The trial has evaluated Vedolizumab in 1,11 ...


Vedolizumab ( Entyvio ) is a humanized monoclonal antibody that inhibits adhesion and migration of leukocytes into the gastrointestinal tract by preventing the alpha4beta7 integrin subunit from bindin ...


Safe, effective treatment options exist for patients with mild-to-moderate Crohn’s disease or ulcerative colitis. However, a significant proportion of patients with moderate-to-severe Crohn’s disease ...


Crohn’s disease and ulcerative colitis are chronic, relapsing inflammatory disorders of the gastrointestinal ( GI ) tract. In both Crohn’s disease and ulcerative colitis, leukocytic infiltration of th ...


Vedolizumab ( Entyvio ) is a humanized version of Act-1, a murine antibody originally developed in the 1980s with activity against the alpha4beta7-integrin heterodimer. During leukocyte extravasation ...


RPC1063 is an orally available, potent, selective sphingosine-1-phosphate 1 receptor ( S1P1R ) agonist, which has been shown to decrease inflammation in animal models of colitis. Stimulation of S1P1 ...


Adalimumab ( Humira ) is the key treatment for ulcerative colitis unresponsive or intolerant to standard treatments. The aim of the study was to assess the efficacy and safety of Adalimumab in treatin ...


The safety and efficacy of Adalimumab ( Humira ) for patients with moderately to severely active ulcerative colitis has been reported up to week 52 from the placebo-controlled trials ULTRA ( Ulcerativ ...